TBCA

Research use only, not for human use.

TBCA is a highly selective CK2 (casein kinase II) inhibitor, IC50 = 110 nM, Ki = 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases.

TBCA is a highly selective CK2 (casein kinase II) inhibitor, IC50 = 110 nM, Ki = 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases.(In Vitro):TBCA inhibits CK2 double mutant (Val66 Ile174) with an IC50 of 0.68 μM. TBCA (0-100 μM; 24 hours) shows a drastic effect on Jurkat cells viability . TBCA dose-dependently inhibits platelet aggregation and secretion induced by various agonists including CRP, 2-MeSADP, AYPGKF and SFLLRN. TBCA also inhibits phosphorylation of PDK1, Akt, and GSK3β induced by AYPGKF.

TBCA (0-100 μM; 24 hours) shows a drastic effect on Jurkat cells viability.TBCA also inhibits CK2 double mutant (Val66 Ile174) with an IC50 of 0.68 μM.TBCA dose-dependently inhibits platelet aggregation and secretion induced by various agonists including 2-MeSADP, AYPGKF, SFLLRN, and CRP. TBCA also inhibits phosphorylation of PDK1, Akt, and GSK3β induced by AYPGKF. Cell Viability Assay Cell Line:Jurkat cells Concentration:0-100 μM Incubation Time:24 hours Result:The viability of Jurkat cells was reduced.

——

Casein Kinase II Inhibitor III, TBCA

Metabolic Enzyme/Protease

Casein Kinase

——

——

——

934358-00-6

463.74

C9H4Br4O2

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (215.64 mM)

C(=C/C(O)=O)\C1=C(Br)C(Br)=C(Br)C(Br)=C1

——

(-20℃)

With Ice Pack

≥ 2 years